Niagen Bioscience, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
NAGE$2.15-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations for the Years Ended and
Consolidated Statements of Operations
(In thousands, except per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Sales, net | $129,423 | $99,597 |
| Cost of sales | 46,234 | 38,011 |
| Gross profit | 83,189 | 61,586 |
| Operating expenses (income): | ||
| Sales and marketing | 35,506 | 29,469 |
| Research and development | 6,330 | 6,016 |
| General and administrative | 27,057 | 18,375 |
| Gain on settlement of royalty obligation | (1,983) | — |
| Total operating expenses, net | 66,910 | 53,860 |
| Operating income | 16,279 | 7,726 |
| Nonoperating income (expenses): | ||
| Interest income, net | 2,127 | 1,129 |
| IRS ERTC disallowance | (214) | — |
| Total nonoperating income, net | 1,913 | 1,129 |
| Income before provision for income taxes | 18,192 | 8,855 |
| Provision for income taxes | 810 | 305 |
| Net income | $17,382 | $8,550 |
| Net income per share attributable to common stockholders: | ||
| Basic | $0.22 | $0.11 |
| Diluted | $0.20 | $0.11 |
| Weighted average common shares outstanding: | ||
| Basic | 79,178 | 75,929 |
| Diluted | 85,436 | 78,125 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.